CEVIS Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 177.20 |
| 52 Week High | SEK 329.00 |
| 52 Week Low | SEK 175.80 |
| Beta | 0.95 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -41.44% |
| 5 Year Change | -26.17% |
| Change since IPO | 240.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| CEVIS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -2.2% |
| 1Y | n/a | -10.6% | 2.4% |
Return vs Industry: Insufficient data to determine how CEVIS performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how CEVIS performed against the UK Market.
Price Volatility
| CEVIS volatility | |
|---|---|
| CEVIS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: CEVIS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CEVIS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 237 | Simon Ostergaard | www.cellavision.com |
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process.
CellaVision AB (publ) Fundamentals Summary
| CEVIS fundamental statistics | |
|---|---|
| Market cap | SEK 4.91b |
| Earnings (TTM) | SEK 96.60m |
| Revenue (TTM) | SEK 602.11m |
50.9x
P/E Ratio8.2x
P/S RatioIs CEVIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEVIS income statement (TTM) | |
|---|---|
| Revenue | SEK 602.11m |
| Cost of Revenue | SEK 188.35m |
| Gross Profit | SEK 413.76m |
| Other Expenses | SEK 317.16m |
| Earnings | SEK 96.60m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.05 |
| Gross Margin | 68.72% |
| Net Profit Margin | 16.04% |
| Debt/Equity Ratio | 13.2% |
How did CEVIS perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield56%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/06 20:12 |
| End of Day Share Price | 2023/05/09 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CellaVision AB (publ) is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Carl-Oscar Bredengen | Berenberg |